Aurum Biosciences is a startup based in the United Kingdom, most recent round Series A.
Aurum Biosciences is a startup founded in 2018 based in the United Kingdom. Its most recent tracked round is Series A.
Aurum Biosciences is a clinical stage biopharmaceutical company focused on developing therapeutics and diagnostics for unmet clinical needs, primarily using oxygen carriers and proprietary MRI software. Its lead product, ABL-101, targets acute ischemic stroke and spinal cord injury, with potential applications in inflammation, oncology, and cardiovascular conditions.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.